To determine the antibody responses after the two doses of inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations in people who were above 65 years old and to evaluate the factors affecting this response
Latest Information Update: 08 Dec 2021
At a glance
- Drugs SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- 01 Jan 2022 Results published in the Journal of Medical Virology
- 08 Dec 2021 New trial record